Pneumonia scoring systems for severe COVID-19: which one is better

PengFei Cheng,JunJun Zhang,Cheng Zhou,Xiang Zhou,JunZhe Yang,MingZhe Qin,Hao Wu,XiaoYang Song,MengDa Xu,BiXi Li

doi:10.1186/s12985-021-01502-6

PengFei Cheng, JunJun Zhang + Show 8 more

Open Access

https://doi.org/10.1186/s12985-021-01502-6

Copy DOI

Abstract

PurposeTo investigate the predictive significance of different pneumonia scoring systems in clinical severity and mortality risk of patients with severe novel coronavirus pneumonia.Materials and methodsA total of 53 cases of severe novel coronavirus pneumonia were confirmed. The APACHE II, MuLBSTA and CURB-65 scores of different treatment methods were calculated, and the predictive power of each score on clinical respiratory support treatment and mortality risk was compared.ResultsThe APACHE II score showed the largest area under ROC curve in both noninvasive and invasive respiratory support treatment assessments, which is significantly different from that of CURB-65. Further, the MuLBSTA score had the largest area under ROC curve in terms of death risk assessment, which is also significantly different from that of CURB-65; however, no difference was noted with the APACHE II score.ConclusionFor patients with COVID, the APACHE II score is an effective predictor of the disease severity and mortality risk. Further, the MuLBSTA score is a good predictor only in terms of mortality risk.

Highlights

A novel coronavirus pneumonia outbreak in Wuhan, China, in December 2019, has had a major impact globally
For patients with COVID, the APACHE Acute physiology and chronic health evaluation II (II) score is an effective predictor of the disease severity and mortality risk
The CURB-65 scoring system [2] is being used as a measure of the severity of community-acquired pneumonia, which can be combined with other clinical parameters to assess if the patients need to be hospitalized or transferred to the intensive care unit (ICU)

Summary

Introduction

A novel coronavirus pneumonia outbreak in Wuhan, China, in December 2019, has had a major impact globally This disease was named as "Corona Virus Disease 2019" (COVID-19), and this new type of corona virus was named as SARS-CoV-2 by the World Health Organization. The APACHE II (acute physiology and chronic health evaluation II) scoring system [3, 4] is being used to evaluate the condition of patients in ICU using 12 parameters. This method is being widely used clinically due to its capability of distinguishing the severity of the disease. With the use of this method, hospitalized patients with viral pneumonia can be classified into relevant risk categories

Methods

Results

Discussion

Conclusion